Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDR sl Assays-Reference-Cited by-同舟云学术

Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDR sl Assays

Published:2017-04 Issue:4 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ajileye Adebisi¹,Alvarez Nataly²³,Merker Matthias⁴⁵,Walker Timothy M.⁶,Akter Suriya⁷,Brown Kerstin¹,Moradigaravand Danesh⁸,Schön Thomas⁹¹⁰,Andres Sönke¹¹,Schleusener Viola⁴,Omar Shaheed V.¹²,Coll Francesc¹³,Huang Hairong¹⁴,Diel Roland¹⁵,Ismail Nazir¹²,Parkhill Julian⁸^ORCID,de Jong Bouke C.⁷,Peto Tim E. A.⁶,Crook Derrick W.⁶¹⁶,Niemann Stefan⁴⁵,Robledo Jaime²³,Smith E. Grace¹,Peacock Sharon J.⁸¹³¹⁷,Köser Claudio U.¹⁷^ORCID

Affiliation:

1. Public Health England West Midlands Public Health Laboratory, Heartlands Hospital, Birmingham, United Kingdom

2. Bacteriology and Mycobacteria Unit, Corporación Para Investigaciones Biológicas, Medellín, Colombia

3. Universidad Pontificia Bolivariana, Medellín, Colombia

4. Division of Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany

5. German Center for Infection Research (DZIF), Partnersite Hamburg-Lübeck-Borstel, Borstel, Germany

6. Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

7. Mycobacteriology Unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium

8. Wellcome Trust Sanger Institute, Hinxton, United Kingdom

9. Department of Clinical and Experimental Medicine, Division of Medical Microbiology, Linköping University, Linköping, Sweden

10. Department of Clinical Microbiology and Infectious Diseases, Kalmar County Hospital, Kalmar, Sweden

11. Division of Mycobacteriology, National Tuberculosis Reference Laboratory, Research Center Borstel, Borstel, Germany

12. Centre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg, South Africa

13. London School of Hygiene & Tropical Medicine, London, United Kingdom

14. National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China

15. Institute of Epidemiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

16. Public Health England, Microbiology Services, London, United Kingdom

17. Department of Medicine, University of Cambridge, Cambridge, United Kingdom

Abstract

ABSTRACT In this study, using the Hain GenoType MTBDR sl assays (versions 1 and 2), we found that some nonsynonymous and synonymous mutations in gyrA in Mycobacterium tuberculosis result in systematic false-resistance results to fluoroquinolones by preventing the binding of wild-type probes. Moreover, such mutations can prevent the binding of mutant probes designed for the identification of specific resistance mutations. Although these mutations are likely rare globally, they occur in approximately 7% of multidrug-resistant tuberculosis strains in some settings.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02169-16

Reference49 articles.

1. Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRslAssay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study

2. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

3. World Health Organization. 2016. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. http://www.who.int/tb/areas-of-work/laboratory/WHOPolicyStatementSLLPA.pdf?ua=1. Accessed 31 July 2016.

4. World Health Organization. 2016. Online annexes (5–8) to WHO policy guidance: the use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. http://www.who.int/tb/areas-of-work/laboratory/OnlineAnnexes_MTBDRsl.pdf?ua=1. Accessed 2 August 2016.

5. World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. World Health Organization, Geneva, Switzerland. https://www.ncbi.nlm.nih.gov/books/NBK390455/. Accessed 3 March 2016.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of Mycobacterium tuberculosis Drug Resistance;Molecular Genetics, Microbiology and Virology;2024-03

2. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine;Therapeutic Advances in Respiratory Disease;2024-01

3. Mycobacterium tuberculosis drugs resistance mechanisms;Molecular Genetics Microbiology and Virology (Russian version);2024

4. Molecular tests for hybridization analysis in the diagnosis of drug susceptibility of <i>M. Tuberculosis</i> to fluoroquinolones and injectable drugs;Tuberculosis and socially significant diseases;2023-12-15

5. Hi-plex deep amplicon sequencing for identification, high-resolution genotyping and multidrug resistance prediction of Mycobacterium leprae directly from patient biopsies by using Deeplex Myc-Lep;eBioMedicine;2023-07